Friday, May 24, 2013

RPG LIFESCIENCES LTD - QUARTERLY RESULTS - FOR Q4 FY 2013 - GOOD IMPROVEMNT - FUTURE APPEALING



RPG LIFESCIENCES LTD

RESULTS FOR Q4 FY 2013


RPG LIFESCIENCES LTD has performed well in Q4 FY 2013 compared to the preceding and corresponding Quarters.

Net Sales for Q4 FY 13 stands at Rs.56.34 Cr; compared to Rs.48.09 cr in the preceding Qtr of Q3 FY 13 ( + 17.16% ); and compared to Rs.41.23 cr in the corresponding quarter of Q4 FY 13 (+36.65%). Net Sales has improved reasonably well in Q4.

Total Expenditure for Q4 FY 13 stands at Rs.53.72 Cr; compared to Rs.53.88 cr in the preceding Qtr of Q3 FY 13 ( -0.3% ); and compared to Rs.47.45 cr in the corresponding quarter of Q4 FY 13 (+13.21%). Total expenditure has gone up less than proportionately compared to Net Sales.

Total Income     for Q4 FY 13 stands at Rs.58.41 Cr; compared to Rs.49.01 cr in the preceding Qtr of Q3 FY 13 ( +19.18% ); and compared to Rs.42.20 cr in the corresponding quarter of Q4 FY 13 (+38.41%). Total Income has gone up impressively both QoQ and YoY.

Cost of materials  for Q4 FY 13 stands at Rs.12.12 Cr; compared to Rs.13.59 cr in the preceding Qtr of Q3 FY 13 ( -10.82% ); and compared to Rs.9.31cr in the corresponding quarter of Q4 FY 13 (+30.18%). Cost of Materials has gone up significantly, though less than proportionately with the Net Sales.

Purchases of SIT for Q4 FY 13 stands at Rs.4.25 Cr; compared to Rs.4.11 cr in the preceding Qtr of Q3 FY 13 ( +3.41% ); and compared to Rs.3.54 cr in the corresponding quarter of Q4 FY 13 (+20.06%).

Employee benefits          for Q4 FY 13 stands at Rs.13.51 Cr; compared to Rs.13.91 cr in the preceding Qtr of Q3 FY 13 ( -2.88% ); and compared to Rs.12.24 cr in the corresponding quarter of Q4 FY 13 (+10.38%).

Depreciation      for Q4 FY 13 stands at Rs.2.53 Cr; compared to Rs.2.57 cr in the preceding Qtr of Q3 FY 13 ( -1.56% ); and compared to Rs.2.60  cr in the corresponding quarter of Q4 FY 13 (-2.69%).

Other expenses for Q4 FY 13 stands at Rs.16.90 Cr; compared to Rs.19.30 cr in the preceding Qtr of Q3 FY 13 ( -12.44% ); and compared to Rs.17.82cr in the corresponding quarter of Q4 FY 13 (-5.16%).

Total expenses  for Q4 FY 13 stands at Rs.53.72 Cr; compared to Rs.53.88 cr in the preceding Qtr of Q3 FY 13 ( -0.3% ); and compared to Rs.47.45cr in the corresponding quarter of Q4 FY 13 (+13.21%). Expenses are thus under reasonable control.
Profit before tax              for Q4 FY 13 stands at Rs.3.53 Cr; compared to Rs.(-)6.35 cr in the preceding Qtr of Q3 FY 13 ; and compared to Rs(-)6.43 cr in the corresponding quarter of Q4 FY 13. At the PBT stage also, the improvement is significant.

Tax Expenses     for Q4 FY 13 stands at Rs.(-)3.87 Cr; compared to Rs.(-)0.26 cr in the preceding Qtr of Q3 FY 13 ; and compared to Rs(-)0.74cr in the corresponding quarter of Q4 FY 13. The lower Tax expenses has significantly enhance the net Profits.

Net Profit            for Q4 FY 13 stands at Rs.7.40 Cr; compared to Rs.(-)6.09 cr in the preceding Qtr of Q3 FY 13 ; and compared to Rs(-)5.69cr in the corresponding quarter of Q4 FY 13. Net Profit has improved decisively and significantly in the 4th quarter.
Face Value of Share is Rs.8.

Paid-up Equity stands at Rs.13.23 Cr.

Basic EPS for Q4 FY 13 stands at Rs.4.48; compared to Rs(-)3.68 in the preceding quarter and Rs.(-)3.44 in the corresponding quarter. This is a significant improvement over both the preceding and corresponding quarters.

Public holding in the company stands at 43.52%.

The improvement in the performance of RPG Lifesciences in Q4 is very good. RPGLIF is acquiring more and more approvals for its products and for its factories, which is good for its long term performance.

 *  *  *  E  N  D  *  *  *

Tuesday, May 14, 2013

SUVEN LIFE SCIENCES Ltd - RESULTS FOR Q4 FY 2013 and fy 2013 - PAT UP good improvement



SUVEN LIFE SCIENCES LIMITED
RESULTS FOR Q4 FY 2013

Suven‘s PAT up by 115% for the year ended Mar 2013

14 May’ 2013 :  – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, has announced its audited financial results for the quarter and year ended 31st Mar 2013. 

Financial Highlights
 for the 4th Quarter ended Mar’ 2013:

Ø Growth in revenue Rs 747 Mn vs.Rs 629 Mn - Up by 23%
Ø Growth in PAT Rs 86 Mn vs. Rs 71 Mn - Up by 21%
Ø Growth in EBIDTA Rs 141 Mn vs. Rs 135 Mn - Up by 4%



Financial Highlights
for the year ended Mar’ 2013:

Ø Growth in revenue Rs 2579 Mn vs.Rs 2042 Mn - Up by 26%
Ø Growth in PAT Rs 308 Mn vs. Rs 144 Mn - Up by 115%
Ø Growth in EBIDTA Rs 542 Mn vs. Rs 250 Mn - Up by 117%

Suven’s major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 347 Mn (13.4% on revenue) for the year ended Mar’ 2013.
The Board has recommended a Dividend of Re 0.30 per share (30% of face value of Rs.1.00 each) for the year 2012-13.

OTHER NEWS ON SUVEN DURING LAST 2 YEARS :

May 10, 2013 :-Suven Life Sciences secures three Product Patents for their NCEs in Canada and Eurasia.
April 17, 2013 : -Suven Life Sciences secures 4 Product Patents for their NCEs in China, Mexico and New Zealand
Feb 12, 2013 : -Suven‘s PAT up by 500 % for the quater ended Dec 2012
Dec 31, 2012 :-Suven Life Sciences secures 3 Product Patents for their NCEs in Eurasia & Canada.
Dec 13, 2012 :-Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea
Nov 15, 2012:-Suven‘s PAT up by 153% for the quarter ended 30th September’ 2012
Oct 04, 2012 :-Suven Life Sciences bags Pharmexcil’s “Platinum Patent Award”
Aug 14, 2012 :-Suven‘s PAT up by 137 % & Turnover up by 58 % for 1st Quarter ended 30th June 2012
Aug 09, 2012 :-Suven Life Sciences secures 4 Product Patents for their NCEs in Australia, Canada, Korea and New Zealand.
July 13, 2012 :-Suven to Present at Alzheimer's Association International Conference (AAIC)
May 22, 2012 :-Suven Life Sciences secures 4 Product Patents for their NCEs in Japan, Australia, Europe and Eurasia
May 04, 2012 :-Suven‘s PAT up by 137% for 4th Quarter ended 31st Mar’2012
April 03, 2012 :--Suven Life Sciences secures 4 Product Patents for their NCEs in China and Korea
February 07, 2012 :-Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USA
January 31, 2012 :-Suven‘s revenue up by 57% and EBIDTA up by 168% for 3rd Quarter ended 31st Dec’2011
December 08, 2011:-Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and Canada
November 14, 2011:-Suven Life Sciences presenting the Pre-clinical data of their NCEs at Society for Neuroscience (SFN-2011) Annual Meeting at Washington DC, USA
November 1, 2011:-Suven‘s revenue up by 31% and spends 18% of revenue on R&D;
October4, 2011:-Suven Life Sciences bags Pharmexcil’s Gold “Patent Award”
September 22, 2011:-Suven Participating at 4th CNS Partnering & Deal Making Conference in USA
September 5, 2011 :-Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and New Zealand
August 18, 2011:-Suven Life Sciences secures 4 Product Patents for their NCEs in the key markets in the world
August 13, 2011:-Suven‘s revenue up by 24% and spends 17% of revenue on R&D
July 18, 2011:-Suven presenting at International Conference on Alzheimer’s disease (ICAD)
June 20, 2011:-Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the world
May 30, 2011:-Suven Spends 20.5% of Revenue on R&D’   PAT up by 48.55% for the year ending March 2011
May 26, 2011:-Suven Life Sciences secures 4 Product Patents for their NCEs in several key markets in the world
May 18, 2011:-Suven’s Alzheimer drug candidate SUVN-502 successfully completed all chronic toxicological (tox) studies and demonstrated very high margin of safety (MOS)
May 09, 2011:-Suven Life Sciences bags “Bio-Excellence Award at Bangalore India Bio 2011”
April 26, 2011:-Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the world
April 5, 2011:-SUVEN’S UNIT-III RECEIVES US FDA ACCEPTANCE
Jan 31, 2011:-Suven spends 24% of revenue on R&D;   PAT up by 55% for for the 3rd quarter ending Dec 2010;
Jan 11, 2011:-Suven’s partnering and fund-raising activity at J.P. Morgan Healthcare Conference 2011

*  *  *  E  N  D  *  *  *

CERA SANITARYWARE LTD - RESULTS - FOR Q4 FY 13 & FOR FY 2013 - Q4 NET SALES UP 57.61 % YoY; Q4 NET PROFIT UP 50% YoY - GOOD PROSPECTS




CERA SANITARYWARE LTD

RESULTS FOR Q4 FY 13 & FOR FY 2013

CERA SANITARYWARE LIMITED has been producing very good results. The Q4 FY 13 results are also quite good. The Quarterly Results details may be seen in the table below with percentage improvement QoQ and also YoY.

On an annual Basis, the company has grown 53% in top line; 44% in bottom line with Basic EPS for FY 13 at Rs.36.51, against Rs.25.32 in previous year. The company has declared and 80% Dividend.

Current Market price is Rs.455. At this price and annual EPS of Rs.36.51, the PE Ratio works out to 12.46. Its future Growth Prospects appear to be quite impressive.

Its Net Sales for FY 13 stands at Rs.487.87 Cr; compared to Rs.319.39 Cr in previous year.

Its Net Profit for the year FY 13 stands at Rs.46.21 Cr; against Rs.32.04 cr in previous year.

Talking about the company's performance, Vikram Somany, Chairman and Managing Director of Cera Sanitaryware Limited said, "CERA's focused endeavors to provide complete bathroom solutions to its customer base across the length and breadth of the country. The strategic planning in terms of product optimisation and leveraging on Cera's strong brand image with well supported penetrating distribution network has helped the company achieving high growth and set new standards for itself."

The CAGR of company during last five years has remained much more than industry growth rate.

"We are confident of sustaining the company's growth in coming years with its business strategies of continuously upgrading product basket, leveraging on strong brand image, optimising product potential, capacity utilization and distribution network-all backed up by well structured sales and marketing plans," Somany added.

RESULTS TABLE - COMPARISON

CERA SANITARYWARE
31-Mar-13
31-Dec-12
%Dif QoQ
31-Mar-12
%Dif YoY
Net Sales
15795.45
12801.98
23.38
10021.93
57.61
Total Expenditure
13990.68
11004.96
27.13
8642.59
61.88
Profit before Intt, Dep. & Taxes
1804.77
1797.02
0.43
1379.34
30.84
Total Income
15795.45
12801.98
23.38
10021.93
57.61
Changes in inventories of FG, WIP and SIT
1459.33
62.37
2239.79
-1258.97
-215.91
Cost of materials
1106.31
1717.73
-35.59
1887.8
-41.4
Purchases of SIT
5325.56
4215.17
26.34
3836.96
38.8
Employee benefits
1616.23
1471.34
9.85
1234.94
30.88
Depreciation
268.56
256.36
4.76
216.77
23.89
Other expenses
4214.69
3281.99
28.42
2725.09
54.66
Total expenses
13990.68
11004.96
27.13
8642.59
61.88
Profit  before tax
1960.18
1796.11
9.13
1455.64
34.66
Tax Expenses
566.81
595.99
-4.9
526.73
7.61
Net Profit
1393.37
1200.12
16.1
928.91
50
Face Value of Share (RS )
5
5
0
5
0
Paid-up Equity
632.74
632.74
0
632.74
0
Diluted EPS
11.01
9.48
16.14
7.34
50
Public holding (%)
44.5
44.6
-0.22
0



*  *  *  E  N  D  *  *  *